Kindred Biosciences IPO Info

Company Name: Kindred Biosciences
Stock Symbol: KIN
Exchange: NASDAQ
Status: Priced
IPO Date: 12/12/2013
IPO Price: 7.00 (59.57%)

Underwriters

BMO Capital Markets and Guggenheim Securities

Amount of Offering: N/A
Number of Shares Offered: 7.5 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A

Company Description

Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company's lead product candidates are CereKin for the treatment of osteoarthritis pain and inflammation in dogs, AtoKin for the treatment of atopic dermatitis in dogs, and SentiKin for the treatment of post-operative pain in dogs.

News Headlines

• Kindred Biosciences (KIN) IPO Opens Sharply Higher
• Kindred Biosciences (KIN) IPO Prices at $7, Middle of Range